Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596731 | 0.78 | — | — | |
| SCHEMBL1188027 | 0.75 | TYR (0.34) | LMNAPTGS1TRPA1CACNA1CTYR | |
| SCHEMBL191957 | 0.73 | TYR (0.38) | LMNATYRALDH1A1MAPK1HTT | |
| SCHEMBL3602717 | 0.73 | TYR (0.40) | LMNAPTGS1TRPA1CACNA1CTYR | |
| SCHEMBL17262605 | 0.73 | TYR (0.33) | LMNAPTGS1TRPA1CACNA1CTYR | |
| SCHEMBL2585466 | 0.73 | TYR (0.33) | LMNAPTGS1TRPA1CACNA1CTYR | |
| SCHEMBL2586636 | 0.70 | IDO1 (0.32) | LMNATYRIDO1 | |
| SCHEMBL162301 | 0.70 | ALDH1A1 (0.37) | LMNATYRALDH1A1MAPK1IDO1 | |
| SCHEMBL8782148 | 0.69 | IDO1 (0.31) | TYRIDO1 | |
| SCHEMBL104124 | 0.67 | TYR (0.58) | LMNAPTGS1TRPA1CACNA1CTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399203-A1 | PRODRUGS OF FENCAMFAMINE | PRAXIS BIORESEARCH, INC. | 2020-12-24 | — | — | US | claimed |
| CN-107082789-B | Method for preparing organic phosphate compound by efficiently esterifying P (O) -OH-containing compound and phenol | 湖南理工学院 | 2020-08-28 | — | — | CN | claimed |
| US-10662146-B2 | Prodrugs of fencamfamine | Praxis Bioresearch, LLC (US) | 2020-05-26 | — | — | US | claimed |
| US-20190023650-A1 | PRODRUGS OF FENCAMFAMINE | Praxis Bioresearch, LLC | 2019-01-24 | — | — | US | claimed |
| EP-3349853-A1 | PRODRUGS OF FENCAMFAMINE | Praxis Bioresearch, LLC (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048720-A1 | PRODRUGS OF FENCAMFAMINE | PRAXIS BIOSCIENCES, LLC (US) | 2017-03-23 | — | — | WO | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | claimed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-6008306-A | COMPOSITION OF STRAINED CYCLOOLEFIN AND A DIVALENT CATIONIC RUTHENIUM OR OSMIUM BOUND TO 1-3 TERTIARY PHOSPHINE LIGANDS, THE PHOSPHINE GROUPS CONTAIN PHENYL SUBSTITUTED BY ALKYL, ALKOXY OR HALOALKYL GROUPS; IMPROVED CATALYTIC ACTIVITY | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-12-28 | — | — | US | claimed |
| EP-0513580-B1 | Alpha-phenyl-acrylic acid derivatives, process for their preparation and their use as parasiticides and fungicides | BASF AG (DE) | 1996-10-23 | — | — | EP | claimed |
| US-5416068-A | Alpha-phenylacrylic acid derivatives, their preparation and their use for controlling pests and harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 1995-05-16 | — | — | US | claimed |
| US-3959332-A | N-(2-NITRO-4-ARYLOXYSULFONYL-PHENYL)-ARYLENEDIAMINES, DYES | SANDOZ LTD. (CH) | 1976-05-25 | — | — | US | claimed |
| JP-10045784-A | — | — | None | — | — | JP | disclosed |
| EP-4452848-B1 | PRECIPITATED SILICA AND METHODS THEREOF | EVONIK OPERATIONS GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250100959-A1 | METHOD FOR STORING REDUCED COENZYME Q10 | KANEKA CORPORATION (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-0360085-A2 | Offset printing and offset dyestuffs | BAYER AG (DE) | 1990-03-28 | — | — | EP | disclosed |
| US-4420437-A | Preparation of a 2-aralkyl-5,5-dialkyl-1,3,2-dioxaphosphorinan-2-one from 2-aralkoxy-5,5-dialkyl-1,3,2-dioxaphosphorinane | WITCO CHEMICAL CORPORATION (US) | 1983-12-13 | — | — | US | disclosed |
| US-4107138-A | Phosphonous and thiophosphonous acid ethers as stabilizers for organic materials | SANDOZ LTD. (CH) | 1978-08-15 | — | — | US | disclosed |
| US-3987097-A | INCREASING AFFINITY FOR ANIONIC DYES | SANDOZ LTD. (CH) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | LMNA 1262/4885PTGS1 1182/4885TRPA1 4420/4885 |
| US-20190023650-A1 | PRODRUGS OF FENCAMFAMINE | FOLR2, FOLR1, CYP4F2 | LMNA 1726/4885PTGS1 326/4885TRPA1 2822/4885 |
| US-10662146-B2 | Prodrugs of fencamfamine | FEN1, PNMT, SLC19A1 | LMNA 3919/4885PTGS1 2356/4885TRPA1 3760/4885 |
| US-20200399203-A1 | PRODRUGS OF FENCAMFAMINE | FOLR2, FOLR1, CYP4F2 | LMNA 1726/4885PTGS1 326/4885TRPA1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.